Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression

Journal of Experimental Medicine

Volumn 191, Issue 7, 2000, Pages 1095-1103

  Song, Kaimei ^a   Chen, Yiguang ^a   Göke, Rüdiger ^a   Wilmen, Andreas ^a   Seidel, Cheryl ^a   Göke, Alexandra ^a   Hilliard, Brendan ^a   Chen, Youhai ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Apoptosis; Autoimmunity; Cytokine; Inflammation; TRAIL

Indexed keywords

ANTIRHEUMATIC AGENT; AUTOANTIBODY; CELL DNA; CELL MEMBRANE PROTEIN; CYTOKINE; HLA DR5 ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA SYNTHESIS INHIBITION; GENE THERAPY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MITOSIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; RAT; RHEUMATOID ARTHRITIS; SYNOVIOCYTE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; CELL CYCLE; HUMANS; JURKAT CELLS; LIGANDS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED DBA; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034599757     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.7.1095     Document Type: Article

References (46)

1. Wiley, S.R., K. Schooley, P.J. Smolak, W.S. Din, C.P. Huang, J.K. Nicholl, G.R. Sutherland, T.D. Smith, C. Rauch, C.A. Smith, and R.G. Goodwin. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:673-682.
2. Pan, G., J. Ni, Y.F. Wei, G. Yu, R. Gentz, and V.M. Dixit. 1997. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 277:815-818.
3. Pan, G., J. Ni, G. Yu, Y.F. Wei, and V.M. Dixit. 1998. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett. 424:41-45.
4. Schneider, P., J.L. Bodmer, M. Thome, K. Hofmann, N. Holler, and J. Tschopp. 1997. Characterization of two receptors for TRAIL. FEBS Lett. 416:329-334.
5. Sheikh, M.S., T.F. Burns, Y. Huang, G.S. Wu, S. Amundson, K.S. Brooks, A.J. Fornace, Jr., and W.S. El-Deiry. 1998. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 58: 1593-1598.
6. Sheridan, J.P., S.A. Marsters, R.M. Pitti, A. Gurney, M. Skubatch, D. Baldwin, L. Ramakrishnan, C.L. Gray, K. Baker, W.I. Wood, et al. 1997. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science. 277:818-821.
7. Walczak, H., M.A. Degli-Esposti, R.S. Johnson, P.J. Smolak, J.Y. Waugh, N. Boiani, M.S. Timour, M.J. Gerhart, K.A. Schooley, C.A. Smith, et al. 1997. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO (Eur. Mol. Biol. Organ.) J. 16:5386-5397.
8. Screaton, G.R., J. Mongkolsapaya, X.N. Xu, A.E. Cowper, A.J. McMichael, and J.I. Bell. 1997. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol. 7:693-696.
9. Emery, J.G., P. McDonnell, M.B. Burke, K.C. Deen, S. Lyn, C. Silverman, E. Dul, E.R. Appelbaum, C. Eichman, R. DiPrinzio, et al. 1998. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273:14363-14367.
10. Wu, G.S., T.F. Burns, Y. Zhan, E.S. Alnemri, and W.S. El-Deiry. 1999. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res. 59:2770-2775.
11. Mariani, S.M., and P.H. Krammer. 1998. Surface expression of TRAIL/Apo-2 ligand in activated mouse T and B cells. Eur. J. Immunol. 28:1492-1498.
12. Jeremias, I., I. Herr, T. Boehler, and K.M. Debatin. 1998. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28:143-152.
13. Walczak, H., R.E. Miller, K. Ariail, B. Gliniak, T.S. Griffith, M. Kubin, W. Chin, J. Jones, A. Woodward, T. Le, et al. 1999. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5:157-163.
14. Ashkenazi, A., R.C. Pai, S. Fong, S. Leung, D.A. Lawrence, S.A. Marsters, C. Blackie, L. Chang, A.E. McMurtrey, A. Hebert, et al. 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104:155-162.
15. Wu, G.S., T.F. Burns, E.R. McDonald III, W. Jiang, R. Meng, I.D. Krantz, G. Kao, D.D. Gan, J.Y. Zhou, R. Muschel, et al. 1997. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17:141-143.
16. Higgins, D.R. 1998. Overview of protein expression in Pichia pastoris. In Current Protocols in Protein Science. J.E. Coligan, editor. John Wiley & Sons, Inc., New York. 5.7.1-5.7.16.
17. Zhang, H., Y. Yang, J.L. Horton, E.B. Samoilova, T. Judge, L.A. Turka, J.M. Wilson, and Y. Chen. 1997. Amelioration of collagen-induced arthritis by Fas (CD95)-ligand gene transfer. J. Clin. Invest. 100:1951-1957.
18. Wilson, G.D. 1998. Cell kinetic studies using a monoclonal antibody to bromodeoxyuridine. In Immunochemical Protocols. Vol. 80, 2nd ed. J.D. Pound, editor. Humana Press, Totowa, NJ. 251-255.
19. Ju, S.T., D.J. Panka, H. Cul, R. Ettinger, M. El-Khatib, D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interaction required for programmed cell death after T-cell activation. Nature. 373:444-448.
20. Dhein, J., H. Walczak, C. Baumler, K.-M. Debatin, and P.H. Krammer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:438-441.
21. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, and D.R. Green. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 373:441-444.
22. Noguchi, P.D. 1993. Use of flow cytometry for DNA analysis. In Current Protocols in Immunology. J.E. Coligan, editor. Sarah Greene, New York. 5.7.1-5.7.3.
23. Maini, R.N., M.J. Elliott, F.M. Brennan, R.O. Williams, C.Q. Chu, E. Paleolog, P.J. Charles, P.C. Taylor, and M. Feldmann. 1995. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol. Rev. 144:195-223.
24. Joosten, L.A., M.M. Helsen, F.A. van de Loo, and W.B. van den Berg. 1996. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 39:797-809.
25. Williams, R.O., M. Feldmann, and R.N. Maini. 1992. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 89:9784-9788.
26. Eliaz, R., D. Wallach, and J. Kost. 1996. Long-term protection against the effects of tumour necrosis factor by controlled delivery of the soluble p55 TNF receptor. Cytokine. 8:482-487.
27. Bettinardi, A., D. Brugnoni, E. Quiros-Roldan, A. Malagoli, S. La Grutta, A. Correra, and L.D. Notarangelo. 1997. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 89:902-909.
28. Sneller, M.C., J. Wang, J.K. Dale, W. Strober, L.A. Middelton, Y. Choi, T.A. Fleisher, M.S. Lim, E.S. Jaffe, J.M. Puck, et al. 1997. Clinical, immunologic, and genetic features of an autoimmune lymphoproliterative syndrome associated with abnormal lymphocyte apoptosis. Blood. 89:1341-1348.
29. Nagata, S., and P. Golstein. 1995. The Fas death factor. Science. 267:1449-1456.
30. Cohen, P.L., and R.A. Eisenberg. 1992. The lpr and gld genes in systemic autoimmunity: life and death in the Fas lane. Immunol. Today. 13:427-428.
31. Nagata, S., and T. Suda. 1995. Fas and Fas ligand: lpr and gld mutations. Immunol. Today. 16:39-43.
32. Mountz, J.D., T. Zhou, H. Bluethmann, J. Wu, and C.K. Edwards III. 1994. Apoptosis defects analyzed in TcR transgenic and fas transgenic lpr mice. Int. Rev. Immunol. 11:321-342.
33. Waldner, H., R.A. Sobel, E. Howard, and V.K. Kuchroo. 1997. Fas- and FasL-defident mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159:3100-3103.
34. Sabelko, K.A., K.A. Kelly, M.H. Nahm, A.H. Cross, and J.H. Russell. 1997. Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159:3096-3099.
35. Giordano, C., G. Stassi, R. De Maria, M. Todaro, P. Richiusa, G. Papoff, G. Ruberti, M. Bagnasco, R. Testi, and A. Galluzzo. 1997. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science. 275: 960-963.
36. Chervonsky, A.V., Y. Wang, F.S. Wong, I. Visintin, R.A. Flavell, C.A. Janeway, Jr., and L.A. Matis. 1997. The role of Fas in autoimmune diabetes. Cell. 89:17-24.
37. Kang, S.M., D.B. Schneider, Z. Lin, D. Hanahan, D.A. Dichek, P.G. Stock, and S. Baekkeskov. 1997. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat. Med. 3:738-743.
38. Muruve, D.A., A.G. Nicolson, R.C. Manfro, T.B. Strom, V.P. Sukhatme, and T.A. Libermann. 1997. Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Hum. Gene Ther. 8:955-963.
39. Itoh, N., A. Imagawa, T. Hanafusa, M. Waguri, K. Yamamoto, H. Iwahashi, M. Moriwaki, H. Nakajima, J. Miyagawa, M. Namba, et al. 1997. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 186:613-618.
40. Fujisawa, K., H. Asahara, K. Okamoto, H. Aono, T. Hasunuma, T. Kobata, Y. Iwakura, S. Yonehara, T. Sumida, and K. Nishioka. 1996. Therapeutic effect of the anti-Fas antibody on arthritis in HTLV-1 tax transgenic mice. J. Clin. Invest. 98:271-278.
41. Kurts, C., F.R. Carbone, M.F. Krummel, K.M. Koch, J.F. Miller, and W.R. Heath. 1999. Signalling through CD30 protects against autoimmune diabetes mediated by CD8 T cells. Nature. 398:341-344.
42. Schneider, P., M. Thome, K. Burns, J.L Bodmer, K. Hofmann, T. Kataoka, N. Holler, and J. Tschopp. 1997. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity. 7:831-836.
43. Degli-Esposti, M.A., W.C. Dougall, P.J. Smolak, J.Y. Waugh, C.A. Smith, and R.G. Goodwill. 1997. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7:813-820.
44. Chaudhary, P.M., M. Eby, A. Jasmin, A. Bookwalter, J. Murray, and L. Hood. 1997. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity. 7:821-830.
45. Seetharaman, R., A.L. Mora, G. Nabozny, M. Boothby, and J. Chen. 1999. Essential role of T cell NF-kappa B activation in collagen-induced arthritis. J. Immunol. 163:1577-1583.
46. Chen, Y., J.-I. Inobe, and H.L. Weiner. 1995. Induction of oral tolerance to myelin basic protein in CD8-depleted mice: both CD4+ and CD8+ cells mediate active suppression. J. Immunol. 155:910-916.